CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $16.27M, above the global median of $16.24M
- PositionOperating margin is 44.2%, higher than 95% of its Biotechnology peers (median -34.2%)
- Interpretations12 currently firing — 1 · 11
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.20%
Annual Rate
TWD 3.33Paid annual
Payout Ratio
67.7%Moderate
Payback Period
45.5 yr
Last Ex-Dividend
Apr 16, 2026
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
High Dividend Payout With FCF And Equity Ratio
→dividend payout intensity
fcf positive 3y
ratio balance equity
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
14.49BTWD454.07M · vs all stocks (USD)
Trailing P/E
30.79xvs Biotechnology peers
Revenue (TTM)
1.08BTWD33.88M · vs all stocks (USD)
Profit Margin
43.77%vs Biotechnology peers
Beta
0.2990xvs all stocks
52-Week Change
3.63%vs all stocks
Market Capitalization
14.49BTWD454.07M · vs all stocks (USD)
Enterprise Value
14.55BTWD456.10M · vs all stocks (USD)
Trailing P/E
30.79xvs Biotechnology peers
Forward P/E
29.30xvs Biotechnology peers
PEG Ratio
0.7646xvs Biotechnology peers
Price to Sales (TTM)
13.40xvs Biotechnology peers
Price to Book (MRQ)
5.45xvs Biotechnology peers
Enterprise to Revenue
13.46xvs Biotechnology peers
Enterprise to EBITDA
29.79xvs Biotechnology peers
Gross Margin
80.24%vs Biotechnology peers
Profit Margin
43.77%vs Biotechnology peers
Operating Margin
44.19%vs Biotechnology peers
Return on Assets (TTM)
11.47%vs Biotechnology peers
Return on Equity (TTM)
23.35%vs Biotechnology peers
Revenue (TTM)
1.08BTWD33.88M · vs all stocks (USD)
Revenue per Share (TTM)
11.19TWDUpdated Aug 21, 2026Quarterly Revenue Growth
23.10%vs Biotechnology peers
Gross Profit (TTM)
796.39MTWD24.96M · vs all stocks (USD)
EBITDA (TTM)
595.69MTWD18.67M · vs all stocks (USD)
Net Income (TTM)
473.27MTWD14.83M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
0.30%vs Biotechnology peers
Operating Cash Flow (TTM)
631.54MTWD19.79M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
519.32MTWD16.27M · vs all stocks (USD)
Trailing Annual Dividend Rate
3.33TWDUpdated Aug 21, 2026Trailing Annual Dividend Yield
2.20%vs all stocks
Payout Ratio
67.70%vs Biotechnology peers
Revenue
1.02BTWDFY2025 · Dec 31, 2025Cost of Goods Sold
296.18MTWDFY2025 · Dec 31, 2025Gross Profit
721.33MTWDFY2025 · Dec 31, 2025Operating Income
438.94MTWD13.75M · vs all stocks (USD)
Pre-tax Income
524.33MTWDFY2025 · Dec 31, 2025Income Tax Expense
94.90MTWDFY2025 · Dec 31, 2025Net Income
429.43MTWDFY2025 · Dec 31, 2025EBIT
525.25MTWDFY2025 · Dec 31, 2025EBITDA (Income Statement)
548.36MTWDFY2025 · Dec 31, 2025Research & Development
238.16MTWDFY2025 · Dec 31, 2025Selling, General & Administrative
44.23MTWDFY2025 · Dec 31, 2025Non-operating Interest Income
27.97MTWDFY2025 · Dec 31, 2025Non-operating Interest Expense
917.00KTWDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00TWDFY2025 · Dec 31, 2025Operating Cash Flow
631.95MTWDFY2025 · Dec 31, 2025Free Cash Flow
630.67MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
222.16MTWDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
524.33MTWDFY2025 · Dec 31, 2025Stock-based Compensation
62.40MTWDFY2025 · Dec 31, 2025Other Non-cash Items
-27.05MTWDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-28.28MTWDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
100.56MTWDFY2025 · Dec 31, 2025Capital Expenditures
-1.28MTWDFY2025 · Dec 31, 2025Net Intangibles (CF)
-4.44MTWDFY2025 · Dec 31, 2025Purchase of Investments
-271.24MTWDFY2025 · Dec 31, 2025Sale of Investments
454.26MTWDFY2025 · Dec 31, 2025Other Investing Activity
-43.03MTWDFY2025 · Dec 31, 2025Net Investing Cash Flow
138.71MTWDFY2025 · Dec 31, 2025Long-term Debt Payments
-250.00MTWDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00TWDFY2025 · Dec 31, 2025Common Stock Repurchase
-349.42MTWDFY2025 · Dec 31, 2025Common Dividends Paid
-407.80MTWDFY2025 · Dec 31, 2025Other Financing Charges
17.80MTWDFY2025 · Dec 31, 2025Net Financing Cash Flow
-989.41MTWDFY2025 · Dec 31, 2025Shares Outstanding
101.77MSharesUpdated Aug 21, 2026Float Shares
74.39MSharesUpdated Aug 21, 2026% Held by Insiders
32.11%vs all stocks
% Held by Institutions
2.48%vs all stocks
Total Cash (MRQ)
1.06BTWD33.13M · vs all stocks (USD)
Total Cash per Share (MRQ)
10.45TWDUpdated Aug 21, 2026Total Debt (MRQ)
232.54MTWD7.29M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0827xvs Biotechnology peers
Current Ratio (MRQ)
1.89xvs Biotechnology peers
Book Value per Share (MRQ)
27.81TWDUpdated Aug 21, 2026Total Assets
2.00BTWD62.81M · vs all stocks (USD)
Total Current Assets
752.68MTWDFY2025 · Dec 31, 2025Total Liabilities
477.80MTWDFY2025 · Dec 31, 2025Total Non-current Assets
1.25BTWDFY2025 · Dec 31, 2025Total Non-current Liabilities
55.26MTWDFY2025 · Dec 31, 2025Total Current Liabilities
422.55MTWDFY2025 · Dec 31, 2025Cash & Cash Equivalents
222.16MTWDFY2025 · Dec 31, 2025Other Short-term Investments
213.50MTWDFY2025 · Dec 31, 2025Accounts Receivable
229.47MTWDFY2025 · Dec 31, 2025Inventory
75.71MTWDFY2025 · Dec 31, 2025Accounts Payable
43.41MTWDFY2025 · Dec 31, 2025Short-term Debt
10.38MTWDFY2025 · Dec 31, 2025Other Current Liabilities
460.00KTWDFY2025 · Dec 31, 2025Long-term Debt
28.37MTWDFY2025 · Dec 31, 2025Other Non-current Liabilities
18.32MTWDFY2025 · Dec 31, 2025Common Stock (Book)
875.97MTWDFY2025 · Dec 31, 2025Retained Earnings
124.96MTWDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.53BTWD47.84M · vs all stocks (USD)
Treasury Stock
0.00TWDFY2025 · Dec 31, 202552-Week Low
120.95TWDUpdated Aug 21, 202652-Week High
184.00TWDUpdated Aug 21, 202652-Week Change
3.63%vs all stocks
Beta
0.2990xvs all stocks
50-Day MA
151.76TWDUpdated Aug 21, 2026200-Day MA
145.87TWDUpdated Aug 21, 2026Avg 10-Day Volume
269.99KSharesUpdated Aug 21, 2026Avg 30-Day Volume
472.80KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
4.92TWDUpdated Aug 21, 202611 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 44.2%, higher than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: 0.44Industry median: -0.34Industry P95: 0.41Peers compared: 261
Profit margin is 43.8%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 0.44Industry median: -0.46Industry P95: 0.43Peers compared: 261
Return on equity is 23.3%, higher than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: 0.23Industry median: -0.22Industry P95: 0.23Peers compared: 261
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.81
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $16.27M, above the global median of $16.24MNotable
Levered free cash flow (USD): 16,273,910.784Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong VTR Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Games Workshop Group PLC
11 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
Tips Music Ltd.
11 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedThree Asset-Base Ratios Elevated
Thyrocare Technologies Ltd.
10 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Dividend Payout With FCF And Equity RatioCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedCash Backing With OCF Coverage And Cash Near Total DebtThree Asset-Base Ratios Elevated